KPV

KPV is a synthetic tripeptide (Lys-Pro-Val) corresponding to the C-terminal amino acids 11-13 of alpha-melanocyte-stimulating hormone (α-MSH). Despite being only three amino acids in length, KPV retains significant anti-inflammatory signaling activity from the parent α-MSH molecule. Importantly, KPV’s anti-inflammatory mechanism has been characterized as independent of melanocortin receptor activation — unlike full-length α-MSH, which acts through MC1R and other melanocortin receptors, KPV appears to enter cells directly and modulate intracellular NF-κB signaling. This receptor-independent mechanism makes KPV unique among melanocortin-derived peptides. KPV has been investigated in preclinical models of mucosal inflammation, dermatitis, and colitis, where researchers have observed effects on inflammatory cytokine profiles and NF-κB nuclear translocation.

KPV has been investigated for its anti-inflammatory activity through NF-κB pathway modulation. Researchers observed that KPV enters cells through a transporter-mediated mechanism (PepT1 in intestinal epithelium) and directly inhibits NF-κB activation by preventing IκBα phosphorylation and subsequent NF-κB nuclear translocation. This inhibition reduces transcription of NF-κB-dependent inflammatory genes, including TNF-α, IL-6, IL-8, and ICAM-1. Studies suggest that KPV’s mechanism is distinct from conventional melanocortin receptor signaling, as the peptide retains anti-inflammatory activity in cells lacking MC1R. In mucosal models, researchers observed that KPV administration was associated with reduced inflammatory cytokine production and maintained epithelial barrier function. The PepT1-dependent uptake mechanism is particularly relevant for intestinal applications, as PepT1 is highly expressed on intestinal epithelial cells, providing a natural route for KPV internalization in the gastrointestinal tract.

NF-κB Inhibition

Brzoska et al. (2008) reviewed the anti-inflammatory mechanisms of α-MSH-derived peptides, including KPV, demonstrating NF-κB-dependent signaling modulation independent of melanocortin receptor activation [1].

Intestinal Inflammation

Dalmasso et al. (2008) investigated KPV in colitis models and demonstrated that the tripeptide was transported into intestinal epithelial cells via PepT1 and exerted anti-inflammatory effects through NF-κB inhibition [2].

Mucosal Biology

Kannengiesser et al. (2008) investigated KPV in a murine colitis model and observed that oral administration was associated with reduced inflammatory parameters and improved histological scores compared to vehicle controls [3].